Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared on X:
“Real-world 1L mRCC decision-making (Meet-URO 33):
- 65% ICI-TKI,
- 20% Nivo+Ipi
- 15% TKI.”
Title: Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33—REGAL study
Authors: Davide Bimbatti, Cecilia Nasso, Domiziana Aspden, Sebastiano Buti, Ludovica Antonj, Alessio Signori, Elena Verzoni, Cristian Lolli, Marilena Di Napoli, Martina Fanelli, Miriam De Lucia, Cristina Masini, Giandomenico Roviello, Daniela Arduini, Roberto Filippi, Alessia Mennitto, Mariella Sorarù, Giovanni Bozza, Luigi Formisano, Carlo Messina, Lucia Bonomi, Annalisa Guida, Emanuela Fantinel, Sarah Scagliarini, Maria Giuseppa Vitale, Silvia Chiellino, Brigida Anna Maiorano, Filippo Maria Deppieri, Paolo Andrea Zucali, Alessia Cavo, Claudia Caserta, Francesca La Russa, Vincenza Conteduca, Francesca Maines, Silvia Zai, Francesco Pierantoni, Massimiliano Icardi, Pasquale Rescigno, Fabrizio Di Costanzo, Giuseppe Luigi Banna, and Sara Elena Rebuzzi.
You can also read: Metastatic Renal Cell Carcinoma in 2026: Frontline Combinations, Post-IO Sequencing, and the Emergence of HIF-2α Inhibition
